To compare the effect of three drugs- methotrexate, apremilast and their combination in patients suffering from psoriasis vulgaris.
Not Applicable
- Conditions
- Health Condition 1: L400- Psoriasis vulgaris
- Registration Number
- CTRI/2019/07/020274
- Lead Sponsor
- Department of Dermatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients of psoriasis vulgaris requiring systemic therapy. (Body surface area > 10% or
PASI score > 10 or non-responsive to topical therapy)
2. Patients above the age of 18 years.
3. Patients consenting for contraception required for methotrexate therapy.
Exclusion Criteria
1. Patients suffering from any other significant systemic illness.
2. History of anti-psoriatic treatment in the last 2 months.
3. Pregnant or lactating women.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the efficacy of apremilast and methotrexate and their combination in patients of psoriasis vulgaris by comparing the PASI score before and after commencement of the therapy. <br/ ><br>Timepoint: 0,2,4,6,8 weeks.
- Secondary Outcome Measures
Name Time Method To assess the safety of all the three treatment modalities by assessing the side effects.Timepoint: 0,2,4,6,8 weeks.